Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and 124I-cG250 PET/CT

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 4, 2011, Pages 411-420

  Lawrentschuk, Nathan ^a,b   Lee, Fook T ^b   Jones, Gareth ^b   Rigopoulos, Angela ^b   Mountain, Angela ^b   O'Keefe, Graeme ^b   Papenfuss, Anthony T ^c   Bolton, Damien M ^a   Davis, Ian D ^a,b   Scott, Andrew M ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HOSPITAL   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Antibodies monoclonal; Diagnostic imaging; Murine; Positron emission tomography; Radioimmunodetection; Radionuclide imaging; Renal neoplasms

Indexed keywords

CARBONATE DEHYDRATASE IX; GIRENTUXIMAB I 124;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORE TEMPERATURE; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; INTERMETHOD COMPARISON; ISOTOPE LABELING; KIDNEY CARCINOMA; MOUSE; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THREE DIMENSIONAL IMAGING; TUMOR XENOGRAFT;

ANIMALS; ANOXIA; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; AUTORADIOGRAPHY; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; IODINE RADIOISOTOPES; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 79959864803     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.03.028     Document Type: Article

References (60)

1. Linehan W.M. Kidney cancer: Opportunity for disease specific targeted therapy. Urol Oncol 2008, 26:542.
2. Gray L., Conger A.D., Eberr M., et al. Concentration of oxygen dissolved in tissues at the time of irradiation is a factor in radiotherapy. British Journal of Radiology 1953, 26:638-648.
3. Collingridge D.R., Young W.K., Vojnovic B., et al. Measurement of tumor oxygenation: A comparison between polarographic needle electrodes and a time-resolved luminescence-based optical sensor. Radiat Res 1997, 147:329-334.
4. Seddon B.M., Honess D.J., Vojnovic B., et al. Measurement of tumor oxygenation: In vivo comparison of a luminescence fiber-optic sensor and a polarographic electrode in the p22 tumor. Radiat Res 2001, 155:837-846.
5. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 1989, 49:6449-6465.
6. Hockel M., Knoop C., Schlenger K., et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993, 26:45-50.
7. Nordsmark M., Overgaard M., Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996, 41:31-39.
8. Nordsmark M., Bentzen S.M., Rudat V., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005, 77:18-24.
9. Brizel D.M., Scully S.P., Harrelson J.M., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996, 56:941-943.
10. Shweiki D., Itin A., Soffer D., et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845.
11. Fang J., Yan L., Shing Y., et al. HIF-1α-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Res 2001, 61:5731-5735.
12. Grabmaier K., Vissers J.L., De Weijert M.C., et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 2000, 85:865-870.
13. Lam J.S., Pantuck A.J., Belldegrun A.S., et al. G250: A Carbonic Anhydrase IX Monoclonal Antibody. Curr Oncol Rep 2005, 7:109-115.
14. Grabmaier K., MC Ad.W., Verhaegh G.W., et al. Strict regulation of CAIX(G250/MN) by HIF-1α in clear cell renal cell carcinoma. Oncogene 2004, 23:5624-5631.
15. Závada J., Závadová Z., Zat'ovicova M., et al. Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br J Cancer 2003, 89:1067-1071.
16. Chia S.K., Wykoff C.C., Watson P.H., et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 2001, 19:3660-3668.
17. Loncaster J.A., Harris A.L., Davidson S.E., et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: Correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001, 61:6394-6399.
18. Giatromanolaki A., Koukourakis M.I., Sivridis E., et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001, 61:7992-7998.
19. Lawrentschuk N., Poon A.M., Foo S.S., et al. Assessing regional hypoxia in human renal tumors using 18F-fluoromisonidazole positron emission tomography. BJU Int 2005, 96:540-546.
20. Oosterwijk E., Debruyne F.M. Radiolabeled monoclonal antibody G250 in renal-cell carcinoma. World J Urol 1995, 13:186-190.
21. Steffens M.G., Boerman O.C., Oosterwijk-Wakka J.C., et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997, 15:1529-1537.
22. Liu Z., Smyth F.E., Renner C., et al. Anti-renal cell carcinoma chimeric antibody G250: Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 2002, 51:171-177.
23. Oosterwijk E., Ruiter D.J., Hoedemaeker P.J., et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986, 38:489-494.
24. Divgi C.R., Pandit-Taskar N., Jungbluth A.A., et al. Preoperative characterization of clear-cell renal carcinoma using iodine-124-labeled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: A phase I trial. Lancet Oncol 2007, 8:304-310.
25. Divgi C. Editorial: What ails solid tumor radioimmunotherapy?. Cancer Biother Radiopharm 2006, 21:81-84.
26. Ziemer L.S., Lee W.M.F., Vinogradov S.A., et al. Oxygen distribution in murine tumors: Characterization using oxygen-dependent quenching of phosphorescence. J Appl Physiol 2005, 98:1503-1510.
27. Scott A.M., Lee F.T., Jones R., et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: Biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res 2005, 11:4810-4817.
28. Rosendahl A.H., Forsberg G. IGF-I and IGFBP-3 augment transforming growth factor-β actions in human renal carcinoma cells. Kidney Int 2006, 70:1584-1590.
29. Lee F.T., Hall C., Rigopoulos A., et al. Immuno-PET of human colon xenograft- bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody. J Nucl Med 2001, 42:764-769.
30. Nikula T.K., Curcio M.J., Brechbiel M.W., et al. A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl Med Biol 1995, 22:387-390.
31. Lindmo T., Boven E., Cuttitta F., et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984, 72:77-89.
32. Tahtis K., Lee F.T., Smyth F.E., et al. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model. Clin Cancer Res 2001, 7:1061-1072.
33. Lim D.J., Liu X.L., Sutkowski D.M., et al. Growth of an androgen-sensitive human prostate cancer cell line, LNCaP, in nude mice. Prostate 1993, 22:109-118.
34. Beniers A.J., Peelen W.P., Schaafsma H.E., et al. Establishment and characterization of five new human renal tumor xenografts. Am J Pathol 1992, 140:483-495.
35. Clarke K., Lee F.T., Brechbiel M.W., et al. Therapeutic efficacy of anti-Lewis (y) humanized 3S193 radioimmunotherapy in a breast cancer model: Enhanced activity when combined with taxol chemotherapy. Clin Cancer Res 2000, 6:3621-3628.
36. Urano M., Chen Y., Humm J., et al. Measurements of tumor tissue oxygen tension using a time-resolved luminescence-based optical oxylite probe: Comparison with a paired survival assay. Radiat Res 2002, 158:167-173.
37. Brurberg K.G., Graff B.A., Rofstad E.K. Temporal heterogeneity in oxygen tension in human melanoma xenografts. Br J Cancer 2003, 89:350-356.
38. OxyLab pO2, OxyLab LDF: Advanced, Tissue Oxygenation and Blood Flow Monitoring Manual 2004, 1-4. Oxford Optronix Ltd.
39. Fillies T., Werkmeister R., van Diest P.J., et al. HIF1-α overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 2005, 5:84.
40. Airley R.E., Loncaster J., Raleigh J.A., et al. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding. Int J Cancer 2003, 104:85-91.
41. Ivanov S., Liao S.Y., Ivanova A., et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001, 158:905-919.
42. Uemura H., Nakagawa Y., Yoshida K., et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999, 81:741-746.
43. Liao S.Y., Aurelio O.N., Jan K., et al. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 1997, 57:2827-2831.
44. Murakami Y., Kanda K., Tsuji M., et al. MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. BJU Int 1999, 83:743-747.
45. Bui M.H., Seligson D., Han K.R., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 2003, 9:802-811.
46. Divgi C.R., Bander N.H., Scott A.M., et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998, 4:2729-2739.
47. Steffens M.G., Boerman O.C., de Mulder P.H., et al. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999, 5:3268s-3274s.
48. Nelson D.W., Cao H., Zhu Y., et al. A noninvasive approach for assessing tumor hypoxia in xenografts: Developing a urinary marker for hypoxia. Cancer Res 2005, 65:6151-6158.
49. Foo S.S., Abbott D.F., Lawrentschuk N., et al. Functional imaging of intratumoral hypoxia. Mol Imaging Biol 2004, 6:291-305.
50. Brown J.M., Le Q.T. Tumor hypoxia is important in radiotherapy, but how should we measure it?. Int J Radiat Oncol Biol Phys 2002, 54:1299-1301.
51. Fyles A.W., Milosevic M., Wong R., et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998, 48:149-156.
52. Schneider B.P., Miller K.D. Angiogenesis of breast cancer. J Clin Oncol 2005, 23:1782-1790.
53. Saitoh J., Sakurai H., Suzuki Y., et al. Correlations between in vivo tumor weight, oxygen pressure, 31P NMR spectroscopy, hypoxic microenvironment marking by β-D-iodinated azomycin galactopyranoside (β-D-IAZGP), and radiation sensitivity. Int J Radiat Oncol Biol Phys 2002, 54:903-909.
54. Vaupel P., Hockel M. Tumor oxygenation and its relevance to tumor physiology and treatment. Adv Exp Med Biol 2003, 510:45-49.
55. Gonzalez Trotter D.E., Manjeshwar R.M., Doss M., et al. Quantitation of small-animal (124)I activity distributions using a clinical PET/CT scanner. J Nucl Med 2004, 45:1237-1244.
56. Thomas D. Laboratory animals and the art of empathy. J Med Ethics 2005, 31:197-202.
57. Tan E.Y., Yan M., Campo L., et al. The key hypoxia regulated gene CAIX is up-regulated in basal-like breast tumors and is associated with resistance to chemotherapy. Br J Cancer 2009, 100:405-411.
58. Esbaugh A.J., Perry S.F., Gilmour K.M. Hypoxia-inducible carbonic anhydrase IX expression is insufficient to alleviate intracellular metabolic acidosis in the muscle of zebrafish, Danio rerio. Am J Physiol Regul Integr Comp Physiol 2009, 296:R150-R160.
59. Nordsmark M., Eriksen J.G., Gebski V., et al. Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol 2007, 83:389-397.
60. Vordermark D., Kaffer A., Riedl S., et al. Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells. Int J Radiat Oncol Biol Phys 2005, 61:1197-1207.